Highlights from

ASCO 2019

American Society of Clinical Oncology annual meeting

Chicago, USA 31 May - 4 June 2019

Nivolumab-mediated adverse events are independent of efficacy in resected advanced melanoma

Prof. Mario Mandalà (Papa Giovanni XXIII Cancer Center Hospital, Italy) provided data from CheckMate 238, plotting treatment-related adverse events (TRAEs) for nivolumab in patients with resected stage 3B/C or 4 melanoma against recurrence-free survival. His comprehensive analysis demonstrated a safety profile consistent with the other nivolumab studies. The majority of TRAEs with adjuvant nivolumab occurred early during treatment, and patients had a reduced frequency of TRAEs after the treatment course. Most TRAEs resolved within 3 months [1].

CheckMate 238 demonstrated that adjuvant treatment with nivolumab significantly improved recurrence-free survival for patients with stage 3/4 melanoma with pathologic involvement of regional lymph nodes >1 mm who have undergone complete resection including total lymphadenectomy, reducing the risk of recurrence or death by 35% compared with ipilimumab (HR 0.65; 97.56% CI 0.53-0.80; P <0.001). Besides showing clear benefit under the nivolumab arm, initial results also showed significantly less toxicity, although it was unclear if toxicity related to efficacy. The proportion of patients under nivolumab arms who had to stop therapy from TRAEs was 8% compared with >30% of those who were on the ipilimumab arms.

In the current study, Prof. Mandalà and colleagues performed a subgroup analysis of CheckMate 238 patients (n=453) using discrete follow-up intervals and interrogated a putative association of these AEs with efficacy (primary endpoint, recurrence-free survival). Patients were followed for safety for up to 100 days following their last dose; as of the previous 18-month database lock, all patients had been off study drug for >100 days. Safety data were analysed within the pre-defined time intervals: 0–3 months of treatment, 3–12 months of treatment, and from the last dose to 100+ days after the last dose.

The incidence of the first onset of TRAEs reported in ≥5% of patients was highest in the 0–3 month time frame; the most common TRAEs with nivolumab were fatigue (28% for 0–3 months vs 6% for 3–12 months vs 2% for +100 days post-last dose), pruritus (16% vs 7% vs 1%, respectively), and diarrhoea (15% vs 7% vs 2%, respectively). Most TRAEs with nivolumab resolved within 3 months of occurrence, except for endocrine AEs, which could have required hormone supplementation, and skin AEs (median overall resolution time of 48 and 22 weeks, respectively). The authors concluded that there was no correlation between TRAEs and recurrence-free survival.

  1. Mandalà M et al. Abstract 9584. An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238). ASCO 2019, 31 May-4 June, Chicago, USA.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.